Linking payment to health outcomes: A taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers

被引:210
作者
Carlson, Josh J. [1 ]
Sullivan, Sean D. [1 ]
Garrison, Louis P. [1 ]
Neumann, Peter J. [2 ]
Veenstra, David L. [1 ]
机构
[1] Univ Washington, Pharmaceut Outcomes Res & Policy Program, Seattle, WA 98195 USA
[2] Tufts Med Ctr, Inst Clin Res & Hlth Policy Studies, Ctr Evaluat Value & Risk Hlth, Boston, MA USA
关键词
Economics; Reimbursement mechanisms; Health policy; Outcomes research; Pay for performance; Risk-sharing; MULTIPLE-SCLEROSIS; COST-EFFECTIVENESS; AUSTRALIA; COVERAGE;
D O I
10.1016/j.healthpol.2010.02.005
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
100404 [儿少卫生与妇幼保健学];
摘要
Objective: To identify, categorize and examine performance-based health outcomes reimbursement schemes for medical technology. Methods: We performed a review of performance-based health outcomes reimbursement schemes over the past 10 years (7/98-010/09) using publicly available databases, web and grey literature searches, and input from healthcare reimbursement experts. We developed a taxonomy of scheme types by inductively organizing the schemes identified according to the timing, execution, and health outcomes measured in the schemes. Results: Our search yielded 34 coverage with evidence development schemes, 10 conditional treatment continuation schemes, and 14 performance-linked reimbursement schemes. The majority of schemes are in Europe and Australia, with an increasing number in Canada and the U.S. Conclusion: These schemes have the potential to alter the reimbursement and pricing landscape for medical technology, but significant challenges, including high transaction costs and insufficient information systems, may limit their long-term impact. Future studies regarding experiences and outcomes of implemented schemes are necessary. (c) 2010 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:179 / 190
页数:12
相关论文
共 39 条
[1]
Reimbursement and clinical guidance for pharmaceuticals in Sweden: Do health-economic evaluations support decision making? [J].
Anell A. ;
Persson U. .
The European Journal of Health Economics, 2005, 6 (3) :274-279
[2]
[Anonymous], NY TIMES
[3]
[Anonymous], 2008, ECONOMIST
[4]
*AUSTR DEP HLTH AG, 2008, IM MES
[5]
Berns Jeffrey S, 2005, Hemodial Int, V9, P255, DOI 10.1111/j.1492-7535.2005.01139.x
[6]
Multiple sclerosis risk sharing scheme: two year results of clinical cohort study with historical comparator [J].
Boggild, Mike ;
Palace, Jackie ;
Barton, Pelham ;
Ben-Shlomo, Yoav ;
Bregenzer, Thomas ;
Dobson, Charles ;
Gray, Richard .
BRITISH MEDICAL JOURNAL, 2009, 339 :1359-1363
[7]
Dealing with uncertainties about cost effectiveness of treatments is difficult problem [J].
Chadwick, D ;
Gray, R .
BRITISH MEDICAL JOURNAL, 2003, 326 (7400) :1212-1213
[8]
CHALKIDOU K, 2006, NICE 2006 TACKLING H
[9]
Making a decision to wait for more evidence: when the National Institute for Health and Clinical Excellence recommends a technology only in the context of research [J].
Chalkidou, Kalipso ;
Hoy, Andrew ;
Littlejohns, Peter .
JOURNAL OF THE ROYAL SOCIETY OF MEDICINE, 2007, 100 (10) :453-460
[10]
Setting up an outcomes guarantee for pharmaceuticals: new approach to risk sharing in primary care [J].
Chapman, S ;
Reeve, E ;
Rajaratnam, G ;
Neary, R .
BRITISH MEDICAL JOURNAL, 2003, 326 (7391) :707-709